Evidence map›Paper›PMID 41838760›Full record

ArticlePloS one2026

Multi-omics analysis identifies CCNB1 as a cell cycle factor driving glioblastoma progression and its inhibition by resveratrol.

Bohan Liu, Dazhao Peng, Yankun Chen, Qiuling Li, Yuedong Hu, Shiyu Liu, Huimin Hu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Bohan LiuDepartment of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Dazhao PengDepartment of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Yankun ChenDepartment of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Qiuling LiDepartment of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Yuedong HuDepartment of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Shiyu LiuDepartment of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Huimin HuDepartment of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.ORCID https://orcid.org/0000-0001-5712-3624

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GBM) is a fast-growing primary brain tumor with high mortality and recurrence rates. Dysregulation of the cell cycle is a hallmark of GBM, and cyclin B1 (CCNB1) is a key regulator of the cell cycle. However, the role of CCNB1 in GBM remains unclear. In this study, we found that CCNB1 mRNA and protein expression levels were significantly higher in GBM tissues than normal tissues. High CCNB1 mRNA expression was associated with poorer prognosis in GBM patients. Single-cell and spatial transcriptomics data revealed that CCNB1+ cells represent a proliferative subcluster in GBM, annotated as proliferative cells, and characterized by the upregulation of cell cycle-related pathways. CCNB1 inhibition decreased the proliferation of GBM cells and impaired cell cycle progression from S phase to G2/M. Additionally, resveratrol could inhibit the expression of CCNB1 and its interacting gene polo-like kinase 1 (PLK1). Importantly, through in vitro and in vivo experiments, we found that resveratrol suppressed GBM cell growth with low toxicity. CCNB1 silencing combined with resveratrol treatment further inhibited the proliferation of GBM cells. Collectively, these data suggest that CCNB1 is highly expressed in GBM and may promote GBM progression. Inhibition of CCNB1 may represent a potential therapeutic strategy for GBM.

Indexed as

Brain NeoplasmsCyclin B1GlioblastomaResveratrolAnimalsCell CycleCell Cycle ProteinsCell Line, TumorCell ProliferationDisease ProgressionGene Expression Regulation, NeoplasticHumansPolo-Like Kinase 1Protein Serine-Threonine KinasesProto-Oncogene ProteinsCCNB1 protein, humanCell Cycle ProteinsCyclin B1Polo-Like Kinase 1Protein Serine-Threonine KinasesProto-Oncogene ProteinsResveratrol

Identifiers

PMID41838760
PMCPMC12991244

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.